Table 14.8
De Novo Posttransplant Solid Malignancy, 1996 to 2005
Liver Recipients

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Total # of Post-Tx Malignancies	235	238	241	231	158	152	143	96	81	49
Malignancies by Type										
Squamous/Basal Cell Carcinoma	96	97	84	86	62	52	51	25	30	17
Melanoma	7	9	4	11	2	3	4	2	-	3
Kaposi Sarcoma	-	-	-	5	2	1	2	-	1	-
Central Nervous System	2	1	5	-	1	3	2	-	2	-
Genito-Urinary (1)	25	23	33	15	17	15	6	7	6	4
Gastro-Intestinal (2)	31	35	38	34	15	17	11	13	8	5
Primary Hepatic Tumor	9	4	12	12	12	6	13	10	6	4
Metastatic Hepatic Tumor	5	8	10	5	6	9	8	10	5	4
Larynx/Bronchi/Lung	31	26	35	26	21	26	28	11	12	5
Breast/Thyroid	9	13	5	14	3	6	6	3	3	3
Leukemia	2	3	3	-	-	1	1	3	2	1
Sarcoma (3)	-	-	-	-	1	-	2	3	2	-
Other	16	12	9	15	13	8	7	7	3	3
Unknown	2	7	3	8	3	5	2	2	1	-
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	40.9%	40.8%	34.9%	37.2%	39.2%	34.2%	35.7%	26.0%	37.0%	34.7%
Melanoma	3.0%	3.8%	1.7%	4.8%	1.3%	2.0%	2.8%	2.1%	-	6.1%
Kaposi Sarcoma	-	-	-	2.2%	1.3%	0.7%	1.4%	-	1.2%	-
Central Nervous System	0.9%	0.4%	2.1%	-	0.6%	2.0%	1.4%	-	2.5%	-
Genito-Urinary (1)	10.6%	9.7%	13.7%	6.5%	10.8%	9.9%	4.2%	7.3%	7.4%	8.2%
Gastro-Intestinal (2)	13.2%	14.7%	15.8%	14.7%	9.5%	11.2%	7.7%	13.5%	9.9%	10.2%
Primary Hepatic Tumor	3.8%	1.7%	5.0%	5.2%	7.6%	3.9%	9.1%	10.4%	7.4%	8.2%
Metastatic Hepatic Tumor	2.1%	3.4%	4.1%	2.2%	3.8%	5.9%	5.6%	10.4%	6.2%	8.2%
Larynx/Bronchi/Lung	13.2%	10.9%	14.5%	11.3%	13.3%	17.1%	19.6%	11.5%	14.8%	10.2%
Breast/Thyroid	3.8%	5.5%	2.1%	6.1%	1.9%	3.9%	4.2%	3.1%	3.7%	6.1%
Leukemia	0.9%	1.3%	1.2%	-	-	0.7%	0.7%	3.1%	2.5%	2.0%
Sarcoma (3)	-	-	-	-	0.6%	-	1.4%	3.1%	2.5%	-
Other	6.8%	5.0%	3.7%	6.5%	8.2%	5.3%	4.9%	7.3%	3.7%	6.1%
Unknown	0.9%	2.9%	1.2%	3.5%	1.9%	3.3%	1.4%	2.1%	1.2%	-
Total # of Patients	174	180	178	175	129	125	120	82	67	42

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
(-) = None in category.
(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.
(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.
(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.
Recipient malignancy statistics are based on voluntary reporting to the OPTN.